# Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

> **NCT00098813** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Thyroid Cancer
- Stage IV Follicular Thyroid Cancer
- Stage IV Papillary Thyroid Cancer

## Interventions

- **DRUG:** romidepsin
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT00098813
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098813, "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00098813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*